Revisiting the Warburg effect: historical dogma versus current understanding

被引:546
作者
Vaupel, Peter [1 ,2 ,3 ,4 ]
Multhoff, Gabriele [5 ,6 ]
机构
[1] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Radiat Oncol, Tumour Pathophysiol Grp, Langenbeckstr 1, D-55131 Mainz, Germany
[2] Univ Freiburg, Univ Med Ctr, Dept Radiat Oncol, Freiburg, Germany
[3] German Canc Consortium DKTK, Partner Site Freiburg, Heidelberg, Germany
[4] German Canc Res Ctr, Heidelberg, Germany
[5] Tech Univ Munich, Ctr Translat Canc Res, Klinikum Rechts Isar, Munich, Germany
[6] Tech Univ Munich, Dept RadioOncol, Klinikum Rechts Isar, Munich, Germany
来源
JOURNAL OF PHYSIOLOGY-LONDON | 2021年 / 599卷 / 06期
关键词
aerobic glycolysis; glycolytic phenotype; lactate accumulation; metabolic reprogramming; tumour acidosis; tumour glucose metabolism; tumour mitochondria; Warburg effect; PYRUVATE-KINASE M2; FUMARATE-HYDRATASE; TUMOR-CELLS; RESPIRATORY IMPAIRMENT; METABOLIC MICROMILIEU; GLUCOSE-METABOLISM; CANCER METABOLISM; BLOOD-FLOW; IN-VIVO; HYPOXIA;
D O I
10.1113/JP278810
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Contrary to Warburg's original thesis, accelerated aerobic glycolysis is not a primary, permanent and universal consequence of dysfunctional or impaired mitochondria compensating for poor ATP yield per mole of glucose. Instead, in most tumours the Warburg effect is an essential part of a 'selfish' metabolic reprogramming, which results from the interplay between (normoxic/hypoxic) hypoxia-inducible factor-1 (HIF-1) overexpression, oncogene activation (cMyc, Ras), loss of function of tumour suppressors (mutant p53, mutant phosphatase and tensin homologue (PTEN), microRNAs and sirtuins with suppressor functions), activated (PI3K-Akt-mTORC1, Ras-Raf-MEK-ERK-cMyc, Jak-Stat3) or deactivated (LKB1-AMPK) signalling pathways, components of the tumour microenvironment, and HIF-1 cooperation with epigenetic mechanisms. Molecular and functional processes of the Warburg effect include: (a) considerable acceleration of glycolytic fluxes; (b) adequate ATP generation per unit time to maintain energy homeostasis and electrochemical gradients; (c) backup and diversion of glycolytic intermediates facilitating the biosynthesis of nucleotides, non-essential amino acids, lipids and hexosamines; (d) inhibition of pyruvate entry into mitochondria; (e) excessive formation and accumulation of lactate, which stimulates tumour growth and suppression of anti-tumour immunity - in addition, lactate can serve as an energy source for normoxic cancer cells and drives malignant progression and resistances to conventional therapies; (f) cytosolic lactate being mainly exported through upregulated lactate-proton symporters (MCT4), working together with other H+ transporters, and carbonic anhydrases (CAII, CAIX), which hydrate CO2 from oxidative metabolism to form H+ and bicarbonate; (g) these proton export mechanisms, in concert with poor vascular drainage, being responsible for extracellular acidification, driving malignant progression and resistance to conventional therapies; (h) maintenance of the cellular redox homeostasis and low reactive oxygen species (ROS) formation; and (i) HIF-1 overexpression, mutant p53 and mutant PTEN, which inhibit mitochondrial biogenesis and functions, negatively impacting cellular respiration rate. The glycolytic switch is an early event in oncogenesis and primarily supports cell survival. All in all, the Warburg effect, i.e. aerobic glycolysis in the presence of oxygen and - in principle - functioning mitochondria, constitutes a major driver of the cancer progression machinery, resistance to conventional therapies, and poor patient outcome. However, as evidenced during the last two decades, in a minority of tumours primary mitochondrial defects can play a key role promoting the Warburg effect and tumour progression due to mutations in some Krebs cycle enzymes and mitochondrial ROS overproduction.
引用
收藏
页码:1745 / 1757
页数:13
相关论文
共 99 条
[1]   The Emerging Facets of Non-Cancerous Warburg Effect [J].
Abdel-Haleem, Alyaa M. ;
Lewis, Nathan E. ;
Jamshidi, Neema ;
Mineta, Katsuhiko ;
Gao, Xin ;
Gojobori, Takashi .
FRONTIERS IN ENDOCRINOLOGY, 2017, 8
[2]   The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia [J].
Agani, FH ;
Pichiule, P ;
Chavez, JC ;
LaManna, JC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (46) :35863-35867
[3]  
Aisenberg A.C., 1961, GLYCOLYSIS RESP TUMO
[4]   Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer [J].
Akella, Neha M. ;
Ciraku, Lorela ;
Reginato, Mauricio J. .
BMC BIOLOGY, 2019, 17 (1)
[5]   Succinate Dehydrogenase Complex An Updated Review [J].
Al Rasheed, Mohamed Rizwan Haroon ;
Tarjan, Gabor .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (12) :1564-1570
[6]   Hypoxia-Modified Cancer Cell Metabolism [J].
Al Tameemi, Wafaa ;
Dale, Tina P. ;
Al-Jumaily, Raked M. Kh ;
Forsyth, Nicholas R. .
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2019, 7
[7]   Pyruvate kinase M2: A simple molecule with complex functions [J].
Alquraishi, Mohammed ;
Puckett, Dexter L. ;
Alani, Dina S. ;
Humidat, Amal S. ;
Frankel, Victoria D. ;
Donohoe, Dallas R. ;
Whelan, Jay ;
Bettaieb, Ahmed .
FREE RADICAL BIOLOGY AND MEDICINE, 2019, 143 :176-192
[8]   From Krebs to clinic: glutamine metabolism to cancer therapy [J].
Altman, Brian J. ;
Stine, Zachary E. ;
Dang, Chi V. .
NATURE REVIEWS CANCER, 2016, 16 (10) :619-634
[9]   Pyruvate kinase M2: A multifarious enzyme in non-canonical localization to promote cancer progression [J].
Amin, Sajid ;
Yang, Peng ;
Li, Zhuoyu .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1871 (02) :331-341
[10]   Cancer Cell Metabolism: One Hallmark, Many Faces [J].
Cantor, Jason R. ;
Sabatini, David M. .
CANCER DISCOVERY, 2012, 2 (10) :881-898